Short Interest in Inventiva S.A. (NASDAQ:IVA) Increases By 34.9%

Inventiva S.A. (NASDAQ:IVA) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 77,700 shares, an increase of 34.9% from the March 31st total of 57,600 shares. Based on an average trading volume of 39,500 shares, the days-to-cover ratio is presently 2.0 days.

Inventiva Stock Down 5.2 %

IVA stock traded down $0.17 during mid-day trading on Tuesday, reaching $3.07. 2,558 shares of the stock traded hands, compared to its average volume of 34,215. The business has a 50-day moving average of $3.63 and a two-hundred day moving average of $3.89. Inventiva has a 52 week low of $2.43 and a 52 week high of $5.05.

Institutional Trading of Inventiva

A hedge fund recently raised its stake in Inventiva stock. Commonwealth Equity Services LLC raised its holdings in shares of Inventiva S.A. (NASDAQ:IVA) by 20.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,435 shares of the company’s stock after purchasing an additional 4,155 shares during the period. Commonwealth Equity Services LLC’s holdings in Inventiva were worth $103,000 as of its most recent filing with the Securities and Exchange Commission. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IVA shares. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Inventiva in a report on Monday, April 1st. Canaccord Genuity Group raised their price target on shares of Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Stifel Nicolaus reduced their price target on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, Lifesci Capital reissued an “outperform” rating on shares of Inventiva in a report on Friday, January 5th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inventiva currently has an average rating of “Buy” and a consensus price target of $17.00.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.